Exhalation Technology

Exhalation Technology is a private UK medtech company developing point-of-care breath diagnostics for respiratory disease, with a current strategic focus on early lung cancer screening. Its lead product, Inflammacheck, is a portable non-invasive device that combines exhaled breath condensate analysis, gas-phase measurements, disposable cartridges, and AI-based pattern recognition to generate rapid risk results in community and primary-care settings. The company was founded in 2003, originally worked in equine respiratory health, and shifted its focus to human health in 2014. Exhalation Technology positions Inflammacheck as an accessible, low-cost screening tool intended to broaden access to earlier lung cancer detection while also supporting broader exhalomics applications in pulmonology and infectious disease. Historical company materials also reference adaptations of the platform such as CoronaCheck and PathoCheck for SARS-CoV-2 and pneumonia-related testing.